Mediwhale’s
Most Defining Moments
20
2025
-
August
- Presented 3 Abstracts at ASPC 2025 Congress on CVD Prevention
-
June
- Awarded NextRise Awards 2025 – Top Innovator Award
- Presented 3 Abstracts at American Diabetes Association 2025 85th Scientific Session
-
May
- Obtained ISO/IEC 27701 certification, GDPR certification
- Signed Strategic Agreement with Dong-A ST
-
February
- Published Study of COPD Risk Prediction at Clnical & Experimental Ophthalmology
2024
-
December
- Obtained ISO27001 Certification
- Won CB Insight Digital Health 50 – Non-Invasive diagnostics
-
November
- Presented 3 abstracts at American Heart Association 2024 Annual conference
-
October
- Presented the research results at the American Society of Nephrology(ASN)
- Awarded 1st place in the diabetic retinopathy and diabetic macular edema Analysis Challenge(MMAC) hosted by The Medical Image Computing and Computer Assisted Intervention(MICCAI)
- CMO, Tyler Rim, selected as one of the top 2% scientists worldwide
-
September
- Press Conference – The future of digital healthcare through Dr. Noon
- Raised $12 milion in Series A2 Funding
-
July
- First prescription at Cardiology department of Severance hospital
-
June
- Selected as a JLABS company by J&J Innovation
-
May
- Published review article of Dr. Noon CVD in Eye and Vision, a journal of Springer Nature
- Presented abstracts of Dr. Noon CVD at ARVO 2024
- Presented abstract of Dr. Noon CKD at ERA 2024
-
January
- Dr. Noon CKD clinical trial protocol approval by Korean Ministry of Food and Drug Administration
2023
-
December
- Obtained New Excellent Technology (NET) designated by the Ministry of Health and Welfare
-
November
- Secured 1st place at the ‘E-nnova Health 2023 Awards’ in Spain
- Presented the research results at the American Heart Association (AHA) and American Society of Nephrology(ASN)
-
October
- CMO, Tyler Rim, selected as one of the top 2% scientists worldwide
-
September
- Awarded 3rd place in the Myoptic Maculopathy Analysis Challenge(MMAC) hosted by The Medical Image Computing and Computer Assisted Intervention(MICCAI)
-
August
- Presented the research results at the 2023 European Society of Cardiology (ESC) conference
- Reti-CKD was designated as the Innovative Medical Device by the Ministry of Food and Drug Safety of Korea
-
June
- Emerged as the winner of the ‘CKD Challenge’ organized by AstraZeneca with the collaboration of Wayra
- Proof of concept paper for Dr. Noon CKD was published in the npj Digital Medicine(IF 15.357), a portfolio journal of the Nature
- Physicians can charge patients for Dr. Noon CVD for diagnosis and treatment purposes as it was selected for the Postponement of New Health Technology Assessment (nHTA)
-
March
- Raises $9 million Series A round for AI-empowered eye scans predicting future diseases
- Joined the MedTech Accelerator program at Mayo Clinic and Arizona State University
-
January
- Joined StartX, a prestigious Silicon Valley-based accelerator program affiliated with Stanford University and Stanford Healthcare
2022
-
November
- Awarded CES Innovation Award 2023 for Reti-CVD
- Presented at the American Heart Association (AHA) Scientific Session in Chicago and the American Society of Nephrology’s (ASN) Kidney Week in Orlando, Florida
- Dr. Noon CVD was confirmed to be the candidate of the New Health Technology Assessment (nHTA) by the HIRA (Health Insurance Review and Assessment Service) in Korea, meaning it is a new medical practice that requires separate compensation by the Korean national insurance
-
October
- Selected in HeartX 2022, a cardiovascular-focused healthcare accelerator program supported by HealthTech Arkansas and MedAxiom
- Joined Innovator’s Network of Center for Health Technology & Innovation at the American Heart Association
- Dr. Noon Fundus & Dr. Noon CVD were registered as medical devices by Food and Drug Administration of Thailand – Category : Cardiovascular risk assessment based on retinal image & eye screening service
-
August
- Dr. Noon CVD was approved as a class III medical device by the Ministry of Food and Drug Safety of Korea
-
June
- Dr. Noon Fundus was installed in Cheonho public health clinic in Seoul as part of a metabolic disease prevention campaign
-
April
- “Retinal photograph-based deep learning predicts biological age, and stratifies morbidity and mortality risk” was published in the peer-reviewed medical journal, Age and Ageing (IF:12.8)
- Dr. Noon Fundus & Dr. Noon CVD were registered as class IIa medical devices by the National Agency of Drug and Food Control (NA-DFC) of Indonesia – Category: Cardiovascular risk assessment based on retinal image & eye screening service
-
February
- Singapore office was opened
- Dr. Noon Fundus & Dr. Noon CVD were registered as class B medical devices by Health Sciences Authority (HSA) of Singapore – Category: Cardiovascular risk assessment based on retinal image & eye screening service
- Dr. Noon Fundus & Dr. Noon CVD were registered as a medical device by Medicines and Healthcare products Regulatory Agency of UK – Category: Cardiovascular risk assessment based on retinal image & eye screening service
2021
-
December
- Dr. Noon Fundus & Dr. Noon CVD were registered as a class IIa medical device by the Australian Registry of Therapeutic Goods (ARTG)
-
October
- Dr. Noon Fundus & Dr. Noon CVD were registered as class B medical devices by the Ministry of Health of Malaysia
-
August
- Raised $2 mil Pre-A round from Korean investors led by SBI Investment
- A patent “AI technology that predicts cardiovascular disease risk through retinal image” was transferred from Singapore Eye Center
-
May
- Dr. Noon Fundus & Dr. Noon CVD obtained CE approval as a class IIa medical device in the EU – Category: Cardiovascular risk assessment based on retinal image & eye screening service
- “Deep-learning-based cardiovascular risk stratification using coronary artery calcium scores predicted from retinal photographs” was published in a top-tier medical journal (The Lancet Digital Health, IF:36.6)
2020
-
December
- Dr. Noon CVD was registered as an innovative medical device by the Ministry of Food and Drug Safety of Korea for screening cardiovascular risk
-
November
- “Prediction of systemic biomarkers from retinal photographs: development and validation of deep-learning algorithms” was published in a top-tier medical journal (The Lancet Digital Health, IF: 36.6)
-
August
- Dr. Noon Fundus was approved as a class III medical device by the Ministry of Food and Drug Safety of Korea
-
May
- ISO 13485 certification was obtained
2019
-
July
- A research collaboration agreement was signed with Singapore Eye Research Institute (SERI)
-
March
- KGMP (Korean Good Manufacturing Practice) certificate was obtained
-
February
- 8 patented technologies were transferred from Yonsei University including “Retinal image analysis method” and “Cardiovascular disease diagnosis through retinal image”
2018
-
August
- A research collaboration agreement was signed with Yonsei University Health System to develop AI-based eye screening technology through retinal image analysis
-
March
- “Retinal image analysis method” technologies were transferred from Yonsei University
2017
-
September
- A leadership team of Kevin Taegeun Choi, Tyler Hyungtaek Rim, and Young Geunyoung Lee was formed
-
March
- 2nd place was awarded in the biggest medical data analysis competition hosted by Asan Medical Center & Microsoft Korea
2016
-
December
- Mediwhale Inc. was founded in Seoul, Korea